Investigating New Treatments for Advanced Penile Cancer
NCT02305654 · RecruitingThis study is looking at treatments for advanced penile cancer. It aims to find out which treatments work best for patients with cancer that has spread to the lymph nodes. Patients may receive standard surgery, chemotherapy, or a combination of radiation and chemotherapy. The trial is designed to help doctors make better treatment decisions in the future.
Locations and contact
This trial is running at 17 locations in 2 countries. 10 of them are currently recruiting.
United States11 locations · 6 recruiting
- Emory University Hospital/Winship Cancer InstituteAtlanta, GeorgiaRecruiting
- Los Angeles County-USC Medical CenterLos Angeles, CaliforniaRecruiting
- Mayo ClinicRochester, MinnesotaRecruiting
- Moffitt Cancer CenterTampa, FloridaRecruiting
- University of Texas M.D. Anderson Cancer CenterHouston, TexasRecruiting
- USC / Norris Comprehensive Cancer CenterLos Angeles, CaliforniaRecruiting
- Fox Chase Cancer CenterPhiladelphia, PennsylvaniaActive Not Recruiting
- Grady Health SystemAtlanta, GeorgiaActive Not Recruiting
- Ohio State University Comprehensive Cancer CenterColumbus, OhioActive Not Recruiting
- University of Chicago Comprehensive Cancer CenterChicago, IllinoisActive Not Recruiting
- University of Oklahoma Health Sciences CenterOklahoma City, OklahomaActive Not Recruiting
United Kingdom6 locations · 4 recruiting
- Norfolk and Norwich University Hospitals NHS Foundation TrustNorwichRecruiting
- St George's Hospital NHS Foundation TrustLondonRecruiting
- University Hospitals of Leicester NHS TrustLeicesterRecruiting
- Velindre NHS TrustCardiffRecruiting
- Swansea Bay University Health BoardSwanseaActive Not Recruiting
- The Royal Marsden NHS Foundation TrustLondonActive Not Recruiting
Who can join
This trial is open to men aged 18 and older who have advanced penile cancer. Participants must provide written consent and have measurable disease. Some health conditions may prevent joining, like certain types of cancer or recent treatments. The trial team will confirm eligibility before enrollment.
What happens during the trial
Participants will be randomly placed in one of several treatment groups. Some will have standard surgery to remove lymph nodes. Others will receive chemotherapy before surgery or chemotherapy with radiation. After surgery, those at high risk for recurrence may receive additional treatments or be monitored. Everyone gets treatment based on their specific condition.
The trial team
The trial is led by the Institute of Cancer Research in the UK. It involves collaboration with the National Cancer Institute and the ECOG-ACRIN Cancer Research Group. The study chairs are Steve Nicholson and Curtis Pettaway, who work at respected cancer centers.
Important dates
The trial started on May 12, 2017, and is currently enrolling participants. It is expected to finish by November 30, 2027.
Additional information
The trial is identified as NCT02305654. It is a Phase 3 trial, meaning it is testing how well the treatments work and their safety. The trial plans to include about 200 participants. This study is not FDA-regulated.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →